Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Catalog # Availability Size / Price Qty
156-B7-100
156-B7-01M
Graph showing bioactivity of Human PD-L1 protein (B7-H1 protein)
1 Image
Product Details
Citations (14)
FAQs
Supplemental Products
Reviews (21)

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF Summary

The non-Fc, His-tagged PD-L1 protein can be found here

PD-L1 Protein His

Explore the full range of bioactive immune checkpoint proteins in addition to PD-L1 Protein

I-O Proteins

Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 0.075-0.75 μg/mL.
Source
Mouse myeloma cell line, NS0-derived human PD-L1/B7-H1 protein
Human PD-L1
(Phe19-Thr239)
Accession # Q9NZQ7
DIEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus
Accession #
N-terminal Sequence
Analysis
Phe19
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
52 kDa (monomer)
SDS-PAGE
70-75 kDa, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

156-B7

Formulation Lyophilized from a 0.2 μm filtered solution in PBS and NaCl.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Data Image

Bioactivity Bioactivity of PD-L1 Protein View Larger

Recombinant Human PD-L1 / B7-H1 Fc Chimera (Catalog # 156-B7) inhibits anti-CD3 antibody-induced IL-2 secretion in human T lymphocytes. The ED50for this effect is 0.075-0.75 µg/mL in the presence of Goat Anti-Human IgG Fc Polyclonal Antibody (Catalog # G-102-C).

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: PD-L1/B7-H1

PD-L1, also known as B7-H1, is one of the ligands for PD-1 and plays a critical role in the regulation of T cell immunity (1-6). The PD-1:PD-L1 interaction initiates a negative signaling cascade in T cells leading to inhibition of T cell activation (2,5,7,8). PD-L1 provides a molecular stop signal to the adaptive immune system helping to distinguish between self and foreign antigens. PD-L1 also plays a role in the development of immune tolerance by promoting T cell anergy (1,5) and enhancing regulatory T cell development (8). In addition, PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (7,9) and inhibits the development of Th17 cells (8). Many cancers exhibit upregulated PD-L1 protein expression, and several cancers with high levels of PD-L1 have been associated with increased tumor aggressiveness and poor prognosis. Using new therapeutics that block the PD-L1:PD-1 interaction has proven successful in the clinic for many cancer types and has sparked great interest in the field of cancer immunotherapy.

The PD-L1 protein is an approximately 65 kDa transmembrane glycoprotein belonging to the B7 family of immune regulatory molecules (10). Mature human PD-L1 protein consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (11). Within the ECD, human PD-L1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (12). PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (10,13,14,16), keratinocytes (9,11), endothelial and intestinal epithelial cells (2,9), as well as a variety of carcinomas and melanoma (12,16).

References
  1. Tsushima, F. et al. (2007) Blood 110:180.
  2. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
  3. Azuma, T. et al. (2008) Blood 111:3635.
  4. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
  5. Park, J.-J. et al. (2010) Blood 116:1291.
  6. Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
  7. Chen, L. et al. (2007) J. Immunol. 178:6634.
  8. Herold, M. et al. (2015) J. Immunol. 195:3584.
  9. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
  10. Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
  11. Dong, H. et al. (1999) Nat. Med. 5:1365.
  12. Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
  13. Tamura, H. et al. (2001) Blood 97:1809.
  14. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
  15. Cao, Y. et al. (2010) Cancer Res. 71:1235.
  16. Dong, H. et al. (2002) Nat. Med. 8:793.
Long Name
Programmed Death Ligand 1
Entrez Gene IDs
29126 (Human); 60533 (Mouse); 499342 (Rat); 574058 (Porcine); 484186 (Canine); 102145573 (Cynomolgus Monkey)
Alternate Names
Avelumab; B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDCD1LG1MGC142296; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1

Citations for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

14 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery
    Authors: JK Fierle, J Abram-Sali, M Brioschi, M deTiani, G Coukos, SM Dunn
    Sci Rep, 2019;9(1):12815.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  2. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
    Authors: W Fu, C Lei, S Liu, Y Cui, C Wang, K Qian, T Li, Y Shen, X Fan, F Lin, M Ding, M Pan, X Ye, Y Yang, S Hu
    Nat Commun, 2019;10(1):4355.
  3. LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer
    Authors: KJ Carpenter, AC Valfort, N Steinauer, A Chatterjee, S Abuirqeba, S Majidi, M Sengupta, RJ Di Paolo, LP Shornick, J Zhang, CA Flaveny
    Sci Rep, 2019;9(1):19530.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries
    Authors: B Cembrola, V Ruzza, F Troise, ML Esposito, E Sasso, V Cafaro, M Passariell, F Visconte, M Raia, L Del Vecchi, AM D'Alise, R Cortese, E Scarselli, N Zambrano, C De Lorenzo, A Nicosia
    Biomed Res Int, 2019;2019(0):6051870.
    Species: Yeast
    Sample Types: Whole Cell
  5. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients
    Authors: A Osa, T Uenami, S Koyama, K Fujimoto, D Okuzaki, T Takimoto, H Hirata, Y Yano, S Yokota, Y Kinehara, Y Naito, T Otsuka, M Kanazu, M Kuroyama, M Hamaguchi, T Koba, Y Futami, M Ishijima, Y Suga, Y Akazawa, H Machiyama, K Iwahori, H Takamatsu, I Nagatomo, Y Takeda, H Kida, EA Akbay, PS Hammerman, KK Wong, G Dranoff, M Mori, T Kijima, A Kumanogoh
    JCI Insight, 2018;3(19):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  6. Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice
    Authors: E Burova, A Hermann, J Waite, T Potocky, V Lai, S Hong, M Liu, O Allbritton, A Woodruff, Q Wu, A D'Orvillie, E Garnova, A Rafique, W Poueymirou, J Martin, T Huang, D Skokos, J Kantrowitz, J Popke, M Mohrs, D MacDonald, E Ioffe, W Olson, I Lowy, A Murphy, G Thurston
    Mol. Cancer Ther, 2017;0(0):.
    Species: N/A
    Sample Types: Protein
    Applications: Bioassay
  7. Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy
    Authors: UM Vogl, L Öhler, M Rasic, JM Frischer, M Modak, J Stöckl
    Anticancer Res., 2017;37(4):1947-1955.
    Applications: ELISA (Standard)
  8. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells
    Sci Rep, 2016;6(0):36722.
    Species: Human
    Sample Types: Protein
    Applications: ELISA (Standard)
  9. Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
    Authors: Robert L Ferris
    Oncoimmunology, 2016;5(10):e1200778.
    Applications: Bioassay
  10. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.
    Authors: Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane L, Ferris R
    Cancer Res, 2015;75(3):508-18.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.
    Authors: Melendreras S, Martinez-Camblor P, Menendez A, Bravo-Mendoza C, Gonzalez-Vidal A, Coto E, Diaz-Corte C, Ruiz-Ortega M, Lopez-Larrea C, Suarez-Alvarez B
    PLoS ONE, 2014;9(12):e113396.
    Species: Human
    Sample Types: Serum
    Applications: ELISA (Standard)
  12. IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells.
    Authors: Chinnadurai R, Copland I, Patel S, Galipeau J
    J Immunol, 2014;192(4):1491-501.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
    Authors: Steidl C, Shah SP, Woolcock BW
    Nature, 2011;471(7338):377-81.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis.
    Authors: Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ
    J. Immunol., 2006;177(12):8844-50.

FAQs

  1. The vial is supposed to contain lyophilized protein but it appears to be empty. Is there anything in it?

    • Pellets can be dislodged during shipping and become disbursed on the vial wall and in the cap. Centrifuge or tap the vial on the benchtop to return this material to the vial bottom. If this does not reveal a pellet, closely inspect the cone of the vial. Some pellets appear as only a tiny amount of material or as a transparent film due to the original buffer formulation. This is a normal appearance for many proteins. For example, if the product is originally lyophilized from a solvent such as acetonitrile or ethanol, and supplied carrier-free, you may not be able to detect the pellet with the naked eye. This does not mean the vial is empty. Reconstitute the vial as directed. After reconstitution, protein concentration can be tested with a spectrophotometer.

  2. What is the recommended method for reconstitution of a lyophilized protein or antibody?

    • Unless more specific directions are on the Certificate of Analysis provided with the product, we suggest the following procedure to ensure optimal recovery: 1. Allow the vial and reconstitution buffer to equilibrate to room temperature. 2. Briefly centrifuge the vial to ensure that all lyophiliate is collected at the bottom of the vial. 3. Add the amount of buffer required to achieve the concentration recommended on the product insert. 4. Allow the vial to reconstitute for 15-30 minutes at room temperature with gentle agitation, like on a rocker platform or rotating by hand.  Avoid vigorous shaking that can cause foaming and protein denaturation. 5. Aliquot into volumes greater than 20 μL and store as indicated on the product insert. If the vial exhibits flakes or particulates, mix the product for a couple of hours at room temperature and then at 4oC overnight. Contact Technical Service if product does not go into solution.  

       

  3. Are R&D Systems recombinant proteins and antibodies sterile?

    • Although the vials are bottled using aseptic techniques, heat-treated vials, and sterile stock solutions, they are not considered or guaranteed to be sterile. If sterile material is needed for an experiment, the material can be filtered through a 0.2 micron filter designed for use with biological fluids.

  4. What is the pI (Isoelectric Point) of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7)?

    • The calculated pI for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7) is 7.1.

  5. Do you have a human IgG1 Fc region that would be a suitable negative control for the linker sequence and Fc region in Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7)?

    • Yes, we offer Recombinant Human IgG1 Fc Protein, CF (Catalog # 110-HG), which contains the human IgG Fc region and linker sequence.

  6. Has Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7), been evaluated on primary cells?

    • Bioactivity of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7) is evaluated by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocyte primary cells. The ED50 for this effect is 0.075-0.75 μg/mL. We recommend reviewing our list of publications under the Citations tab on the product-specific web page to find reported use of our products in similar experimental layouts.

View all Proteins and Enzyme FAQs

Reconstitution Buffers

Reviews for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Average Rating: 4.9 (Based on 21 Reviews)

5 Star
90.48%
4 Star
4.76%
3 Star
4.76%
2 Star
0%
1 Star
0%

Have you used Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 06/19/2020
Application: Binding assay/Protein-protein interaction
Reason for Rating: Tested binding of PDL1-Fc w/ PD-1 using Octet. KD ~1.5uM

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 11/15/2019
Application: Binding assay/Protein-protein interaction

HEK cells expressing mCherry alone (LEFT) or hPD-1 mCherry (RIGHT) were incubated with 0.25 ug of hPD-L1 hIgG1. Binding was monitored by flow cytometry using an anti-human 488 secondary antibody.


Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 12/06/2018
Application: Stem/Immune cell maintenance or differentiation

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 10/24/2018
Application: Cell Adhesion

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 10/12/2018
Application: Enzymatic activity in vitro

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 09/28/2018
Application: CellProlif

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 08/26/2018
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 04/12/2018
Application: SDS-PAGE Control

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 03/30/2018
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 03/15/2018
Application: SDS-PAGE Control

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 03/11/2018
Application: SDS-PAGE Control

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 02/07/2018
Application: Binding assay/Protein-protein interaction
Reason for Rating: Binding observed.

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 12/18/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 12/06/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 12/01/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 11/27/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 11/18/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 07/20/2017
Application: Binding assay/Protein-protein interaction

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 07/20/2017
Application: Cell Adhesion

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 07/14/2017
Application: SPR assay for Kinetics between PDL-1 and AntiPDL-1 Antibody

SPR experiment


Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
By Anonymous on 05/23/2017
Application:

Using Octet, we tested the ability of B7-H1/PD-L1 to bind recombinant PD-1 (R&D 8986-PD-100) and found them to specifically bind to each other.